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Cristiane Alves Villela-Nogueira4, Turán Péter Ürményi1,2, Amilcar Tanuri5, Edson Rondinelli1,2,4 and Rosane Silva1,2*Abstract: About sixty thousand new cases of Hepatitis C virus (HCV) infection are recorded in Brazil each year.
These cases are currently treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) with an overall success rate
of 50%. New compounds for anti-HCV therapy targeted to the HCV NS3 protease are being developed and some
already form the components of licensed therapies. Mapping NS3 protease resistance mutations to protease
inhibitors or anti-viral drug candidates is important to direct anti-HCV drug treatment.
Methods: Sequence analysis of the HCV NS3 protease was conducted in a group of 68 chronically infected patients
harboring the HCV genotype 1. The patients were sampled before, during and after a course of PEG-IFN-RBV
treatment.
Results: Resistance mutations to the protease inhibitors, Boceprevir and Telaprevir were identified in HCV isolated
from three patients (4.4%); the viral sequences contained at least one of the following mutations: V36L, T54S and
V55A. In one sustained virological responder, the T54S mutation appeared during the course of PEG-IFN and RBV
therapy. In contrast, V36L and V55A mutations were identified in virus isolated from one relapsing patient before,
during, and after treatment, whereas the T54S mutation was identified in virus isolated from one non-responding
patient, before and during the treatment course.
Conclusions: The incidence and persistence of protease resistance mutations occurring in HCV from chronically
infected patients in Brazil should be considered when using protease inhibitors to treat HCV disease. In addition,
patients treated with the current therapy (PEG-IFN and RBV) that are relapsing or are non-responders should be
considered candidates for protease inhibitor therapy.
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Median Age 54.00 56.00 56.00 55.00
Median BMI 25.96 27.15 24.58 25.49
Male (%) 62 40 56 56
REL, Relapsing; NR, Non-Responder; SVR, Sustained Virological Response; BMI,
Body Mass Index.
No statistically significant differences were observed between the SVR, REL
and NR groups (p > 0.4, G-test and Chi-square test).
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Infection with hepatitis C virus (HCV) is a global health
problem. The World Health Organization (WHO) [1] esti-
mates that 3% of world’s population is infected with HCV.
Chronic HCV can lead to complications like cirrhosis and
hepatocellular carcinoma (HCC), which are the main
reasons for liver transplantation [2]. There are three million
people infected with HCV in Brazil, with regional differ-
ences in the infection rates observed across the country [3];
these differences range from 0.28% in central and western
regions to 0.62% in the north. According to the National
Information System on Disease Notification (SINAN) of
the Brazilian Ministry of Health, between 1999 and 2009,
60,908 new cases of hepatitis C were recorded [4].
Treatment of chronic hepatitis C infections with pegy-
lated interferon (PEG-IFN) and ribavirin (RBV) results in a
sustained virological response (SVR) in only about 50% of
the patients treated. SVR is characterized by undetectable
levels of HCV RNA when patients are assessed 24 weeks
post-treatment. Lower response rates are found in indivi-
duals infected with the HCV genotype 1, the most common
genotype worldwide [5]. In Brazil, some studies have
described the prevalence of genotype 1 [3,6,7]. Hence, many
direct-acting antiviral compounds are being considered for
anti-HCV therapy [8]. The main targets are the viral
protein RNA-dependent RNA polymerase (NS5B) [9]and
the serine protease NS3/4A. Treatment success has been
obtained with the NS3 protease inhibitors (PIs) Telaprevir
[10,11] and Boceprevir [12,13], both of which have been
approved for clinical use by the US Food and Drug Admin-
istration (FDA) and the Brazilian National Agency for
Sanitary Vigilance (ANVISA). Studies on Serine Protease
Inhibitor Therapy (SPRINT) have aimed to establish the
safety and efficacy of boceprevir or telaprevir when added
to standard peginterferon and ribavirin therapy; such stu-
dies have shown that sustained virological responses in
patients can reach 70% [14-16]. However, resistance muta-
tions against HCV PIs can limit the effectiveness of such
treatments. Genetic variants that confer resistance to PIs
are being found in treatment-naïve patients [17-23].
Because of the lack of a proofreading mechanism during
HCV genome replication, extensive sequence variability in
the viral population can be found in the sera of
HCV-infected patients. The genetic variability of circulating
HCVs can affect the treatment and persistence of the virus,
and poses a great challenge for vaccine development [24].
Nevertheless, few studies have shown the presence of pri-
mary resistance mutations in the Brazilian population [25].
In this study, we analyzed the dynamics of the
appearance of primary resistance mutations to NS3
protease inhibitors and identified specific mutations
in the NS3 protease gene in a cohort of Brazilian
patients chronically infected with HCV genotype 1. We
investigated the presence of such resistance mutationsin the cohort before, during, and after treatment with
PEG-IFN and RBV.
Results
Genetic variability of the HCV isolates
Blood samples were taken from 81 patients before treat-
ment (naïve) with PEG-IFN and RBV. However, 13 patients
were removed from the study due to their loss at follow up.
Viral RNA was extracted from the serum of the remaining
68 patients from which the NS3 protease gene region was
amplified and sequenced. Of the 68 patients analyzed, 26
achieved a sustained virological response (SVR) (38.2%),
10 were relapsing (REL) (14.7%), while 32 were non-
responders (NR) (47.1%). Table 1 summarizes the main
characteristics of the study population. The 38 men and
30 women (median age 55) possessed body mass indices
ranging from 25 to 27.
The evolutionary parameters, dN and dS, along with
dN/dS ratios were calculated to evaluate whether evolu-
tionary selective pressures had acted on the predominant
HCV sequences. The results of these tests showed nega-
tive selective pressure on the sequences as all of the dN/
dS ratios were <1 (0.05 – 0.06). No statistically significant
differences in genetic diversity were observed in the study
groups using AMOVA and Fst analysis (data not shown).
Monitoring NS3 protease resistance mutations over time
Despite the presence of NS3 amino acid mutations in
viruses isolated from the 68 patients studied, 3 (4.4%)
had well-known resistance mutations to NS3 protease
inhibitors, namely, V36L, T54S and V55A mutations.
The temporal dynamics of these mutations were moni-
tored before, during and after treatment with PEG-IFN
and RBV in the patients (Table 2). The T54S mutation
was detected on the seventh day of treatment in one
SVR patient. In contrast, the V36L and V55A mutations
in one REL patient were detected before, during and
after treatment. There was a period where HCV RNA
became undetectable during treatment. Six months after
the treatment ended, however, the mutations became
detectable once more as a result of relapse responses.
Otherwise, one NR patient had the NS3 T54S mutation at
all of the time points until the treatment was interrupted.
Table 2 Dynamics of well-known protease inhibitor
resistance mutations in the viral NS3 protease gene over
time from patients infected with the Hepatitis C virus
Treatment Time Patient ID
(Genotype – Treatment response – Mutation)
PEG-IFN/RBV Pat A Pat B Pat C
(1b – SVR – T54S) (1a – REL –
V36L/V55A)
(1a – NR –
T54S)
Before T 36L/55A S
During 48 h T* 36L/55A S
7d S** 36L/55A S
30d *** *** S
3 m - *** S
6 m - - S
12 m - - Nb
After 18 m - 36L/55A Nb
SVR, Sustained Virological Responder; REL, Relapsing; NR, Non-Responder, -,
Undetectable HCV RNA; Nb, No blood was collected. h, hours; d, days;
m, months.
Viral loads ranged from 4 × 104 to 4 × 106 unless indicated by *. Viral load: *
7.0 × 102, ** 2.6 × 103, and *** <500 IU/ml.
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D81, and S139 of the NS3 protease (which leads to
nonfunctional enzymes) were detected in any of the
isolates studied (data not shown).
Discussion
This study evaluated heterogeneity in the HCV NS3
protease sequences isolated from HCV from a group of
Brazilian patients with chronic hepatitis C whose responses
to PEG-IFN and RBV treatment (SVR, REL and NR) were
being monitored. We assessed genetic variability and the
presence of protease inhibitor resistance mutations in the
NS3 protease in the isolates before, during, and after treat-
ment in patients with viral loads > 500 IU/ml. We investi-
gated specific protease inhibitor resistance mutations,
namely, V36A/L/M/G, Q41R, F43C/S, T54S/A, V55A,
Q80R/K, S138T, R155K/T/G/I/Q/M/S/L and A156S/T/V/I.
Of the 68 patients analyzed 3 (4.4%), had at least one of the
mutations known to confer telaprevir and boceprevir resis-
tance (V36L, T54S and V55A). These resistance mutations
have been described previously [17-22]. In Brazil, know-
ledge is lacking about the temporal changes that occur in
PI resistance mutations during the course of IFN/RBV
treatment. One report [25] described the presence of V36L
and T54S in HCVs in a group of Brazilian patients chroni-
cally infected with HCV. Recent studies have also high-
lighted the presence of naturally ocurring mutations in the
NS3 protease in patients. For example, a study of four
Spanish patients identified V36A, T54A, V55A, R155S, and
A156T/V mutations in the NS3 protease [26]. In addition,
a Japanese study identified T54S, Q80K, I153V and D168ENS3 protease mutations among 261 patients (13.4%
had a single mutation, while 2.3% had double mutations)
[27]. NS3 protease mutations (V36L, T54S, V55A/I, and
Q80K/L) were also observed in 29% of genotype 1a
patients in an Italian population [28].
In the present study, V36L, T54S and V55A mutations
were identified in Brazilian patients treated with PEG-IFN
and RBV. To assess the maintenance of protease mutation
variants, this analysis was performed before, during and
after treatment completion, thus allowing us to determine
the fate of the genetic variants over an 18 months period.
Negative selective pressure was observed acting on the
NS3 protease region analyzed here. In addition, the
observed mutations may confer resistance to telaprevir
and boceprevir, making it possible to predict that patients
harboring viruses with such mutations may not benefit
from a future treatment with these drugs; therefore, the
null responder patients should be engaged in the new
Protease Therapy Protocol [10,12,16,29]. These two drugs
(Boceprevir and Telaprevir), already approved by FDA
and by ANVISA in Brazil [30], are now components of
licensed therapies. Thus, mapping NS3 protease resistance
mutations to protease inhibitors may be an important tool
to direct anti-HCV treatment.Methods
Study population
Patients were recruited between April 2006 and August
2008 at the Hepatology Clinic of the Hospital Universitário
Clementino Fraga Filho (HUCFF), Rio de Janeiro (RJ),
Brazil. Patients chronically infected with HCV showing
liver disease and detectable HCV RNA were treated with
PEG-interferon α-2b (1.5 μg/kg once a week) and ribavirin
(1,000-1,250 mg/day according to body weight and patients
weighing more than 75 kg received 1,250 mg/day) for
12 months. Patients with undetectable serum HCV RNA
6 months after treatment were considered to have sus-
tained virological responses (SVR). REL are patients that
have undetectable viral loads (serum) during treatment
and relapses after 6 months of treatment. Patients who fail
to suppress serum HCV RNA by at least 2 logs after three
months of treatment were considered to be non-
responders (NR). Blood samples were collected from 68
patients infected with the HCV genotype 1a (n = 37) or 1b
(n = 31) before (treatment-naïve), during (48 hours, 7 days,
30 days, 3 months, 6 months, 12 months) and 6 months
after the end of treatment to evaluate SVR.Ethical approval
Written informed consent was obtained from every
patient, previously approved by the ethics committee of
the Hospital of Federal University of Rio de Janeiro by
the number 166/05 in 2005.
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HCV RNA was isolated from 100μL of serum using a
QIAampWMinEluteW Virus Spin kit (Qiagen Inc., Valencia,
CA). Isolation was performed according to manufacturer’s
instructions.RT-PCR amplification of the NS3 protease gene
Reverse transcription (RT) was done using the High
Capacity cDNA Archive Kit (Applied Biosystems, Inc.,
Foster City, California, USA) according to manufacturer´s
instructions. A nested PCR was done to amplify the NS3
protease gene using degenerate external forward (50 GC
DCCYATYACRGCBTAYKCYCARCAGAC 30) and reverse
(50 ACYTTRGTGCTYTTRCCGCTRCCRGTGGG 30) pri-
mers and internal forward (50 CBTAYKCYCARCAGACR
MGRGGC 30) and reverse (50 GGRGWBGARTTRTCY
GWRAABACCGG 30) primers. The PCR mixture for both
rounds of nested PCR contained 0.15 mM dNTPs, 2 mM
MgCl2, 0.3 mM forward and reverse primers and 1
unit of Platinum Taq DNA polymerase (Invitrogen,
Carlsbad, CA, USA). The PCR protocol consisted of
5 min at 94°C, 30 cycles of 30 s at 94°C, 30 s at 55°C and
60 s at 72°C, and a final 10 min at 72°C. The resulting
555-bp PCR products were purified using the Montage
PCR Centrifugal Filter Devices (Millipore, Bedford, MA,
USA) before sequencing.Sequence analyses of the viral NS3 protease gene
Purified PCR products were directly sequenced using
internal forward and reverse primers. Amplicons were
sequenced using a Big DyeW Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Inc., Foster City,
California, USA) and ABI Genetic Analyzer 3130. Sequence
analysis was done using Geneious 4.7.5 [31] and MEGA 4.1
software. All of the sequences obtained were submitted to
GenBank under the following consecutive accession num-
bers: JX106306 to JX106345. Amino acid sequences were
aligned and compared to the HCV reference sequence (1a
genotype H77) (accession number AF009606) [32,33]. Evi-
dence of evolutionary selective pressure on several aligned
predominant sequences was determined by calculating the
dN/dS ratio, where dN represents a non-synonymous site
in which the nucleotide alteration leads to an amino acid
change, while dS is a synonymous site in which the nucleo-
tide alteration does not change the corresponding amino
acid. dN/dS ratios were calculated using the Synonymous
Non-Synonymous Analysis Program (SNAP) [34]. Genetic
diversity (d) between the most common sequences was
assessed using MEGA 4.1 software with the nucleotide
model Maximum Composite Likelihood. An Analysis of
Molecular Variance (AMOVA) and population pairwise Fst
vales were assessed using Arlequin software with the
Tamura 3 parameter as the distance method.Abbreviations
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